Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders
about
Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2.alpha-Synuclein and neuronal cell deathLaunching invasive, first-in-human trials against Parkinson's disease: ethical considerationsParkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1Ca2+ binding to alpha-synuclein regulates ligand binding and oligomerizationMagnesium inhibits spontaneous and iron-induced aggregation of alpha-synucleinSynphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by alpha-synucleinDequalinium-induced protofibril formation of alpha-synucleinAlpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicityParkinson-related parkin reduces α-Synuclein phosphorylation in a gene transfer modelParkin accumulation in aggresomes due to proteasome impairmentParkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and alpha-synuclein mutations promote Tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitroMolecular determinants of α-synuclein mutants' oligomerization and membrane interactionsPre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease modelsc-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's diseaseProgressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteinsMisfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathiesGlial cells as intrinsic components of non-cell-autonomous neurodegenerative diseaseCurcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st centurySecondary structure and dynamics of micelle bound beta- and gamma-synucleinProtein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseasesSubcellular localisation, secretion, and post-translational processing of normal cochlin, and of mutants causing the sensorineural deafness and vestibular disorder, DFNA9Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's modelsDopamine-dependent neurodegeneration in rats induced by viral vector-mediated overexpression of the parkin target protein, CDCrel-1Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES- derived cell model of primary ParkinsonismDeletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred miceMouse Genetic Models of Human Brain DisordersEvaluation of Models of Parkinson's DiseaseMouse models of Parkinson's disease associated with mitochondrial dysfunctionOxidative stress and cerebral endothelial cells: regulation of the blood-brain-barrier and antioxidant based interventionsExploring the accessible conformations of N-terminal acetylated α-synucleinGenetically engineered mouse models of Parkinson's diseaseThe involvement of microRNAs in neurodegenerative diseasesA progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") miceAdult hippocampal neurogenesis in Parkinson's disease: impact on neuronal survival and plasticityHDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?Impaired Brain Dopamine and Serotonin Release and Uptake in Wistar Rats Following Treatment with CarboplatinBehavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease.Characterization of cognitive deficits in rats overexpressing human alpha-synuclein in the ventral tegmental area and medial septum using recombinant adeno-associated viral vectorsNeuropathology in mice expressing mouse alpha-synuclein
P2860
Q21135493-9FCC0288-6C41-48AE-B416-F104EA497357Q21202835-9E07767F-9F1D-45D5-B945-00E5DDB33A95Q24289526-2F8A8174-914D-4E8E-9634-F903FD5B5C2BQ24290518-4C4C16C7-06CC-4E3D-BE19-CFFA527D7AA6Q24291150-83EF67E6-6BDE-49AF-B3A6-E4BCC3346D80Q24292317-A4C40E6A-E1E7-4C36-994D-7098B58E9235Q24294532-F570B27F-41B5-4774-BDFB-BD1DA8D7D886Q24298122-53E31F0E-961C-4396-BC30-6712313EB05CQ24301946-36F28EAC-6DDA-4D2A-85F4-F2C2EBA7FD65Q24305472-76CD16CC-2360-4559-8CF9-AB3E4362E5E9Q24308757-1CCD7651-506F-416E-956B-A917AFD1EEC0Q24311461-C5D2F605-843F-4BD0-9354-C10E5AE90039Q24312185-9FD41900-17BB-46D5-A065-E27C5D5E5318Q24315670-20461173-F601-4869-8355-03E91236DDC9Q24318974-548491CB-75D0-4D7E-AB96-A9E826723C52Q24329069-BD62A7FF-55EF-466E-96E5-DECDBD9DA1D7Q24554351-596A806D-B211-4EF3-B8C6-9DD6C10A3999Q24621854-F4084452-AB99-479D-A51D-C72881FE86E4Q24630927-43F904A6-AE00-4A27-8014-35535844575DQ24647859-48818A8D-5F46-4579-A294-73D1099BE862Q24650014-DFEA7E33-396A-412B-98FF-570668818B11Q24676750-45916E4A-0A9A-40EA-AD56-7EACB8A5C9C5Q24683059-9410164E-5490-48D1-B42B-181CC37F7456Q24683066-260772CE-D6E8-4A71-A294-2966A1F27F8EQ24797276-E7138F67-FE26-4AD3-BAAB-57F90DC7FDA5Q24805405-6EE57422-B875-4DC9-913D-1C14093E73DBQ26752246-3DCAA682-51DC-40DB-A57E-B7C42F14E39CQ26772843-DE0E2599-5283-4940-BC68-486CBDC14F44Q26829851-75FBDE9F-A828-4E16-A6CE-F244CD0E2D52Q26851676-BB9CC813-9D12-414C-89F8-7329D2AA0E4DQ26852660-39E1CFE6-4802-41E7-A85D-B2F63E745218Q26852964-B9AE5891-A28E-41DC-8DA1-30D272FE4D4DQ26858788-8298E104-8E98-4A64-A7F9-59C5D89AB550Q26859072-0E59637F-3311-41B7-B425-DF6017EF4E89Q26862840-BB529973-6593-4F60-81F6-B9CF73C30C86Q27015801-34008580-7E07-4DC3-8FA3-C16A9A086DB4Q27300384-233DF160-B44B-4C42-BE24-3A6079C9A976Q27310355-27E2EFAB-2669-4D22-8E49-7688355B7D32Q27318127-FA22323B-0099-4BD6-9DE8-B1754620D052Q27320029-E9EB9870-20B1-418C-A501-C6D03A695A45
P2860
Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Dopaminergic loss and inclusio ...... or neurodegenerative disorders
@ast
Dopaminergic loss and inclusio ...... or neurodegenerative disorders
@en
type
label
Dopaminergic loss and inclusio ...... or neurodegenerative disorders
@ast
Dopaminergic loss and inclusio ...... or neurodegenerative disorders
@en
prefLabel
Dopaminergic loss and inclusio ...... or neurodegenerative disorders
@ast
Dopaminergic loss and inclusio ...... or neurodegenerative disorders
@en
P2093
P3181
P1433
P1476
Dopaminergic loss and inclusio ...... or neurodegenerative disorders
@en
P2093
Hashimoto M
Rockenstein E
Veinbergs I
P304
P3181
P356
10.1126/SCIENCE.287.5456.1265
P407
P577
2000-02-18T00:00:00Z